Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma

Key Inclusion Criteria: * Patients with histologically verified, unresectable or metastatic, HER2-negative, adenocarcinoma of the esophagus or stomach * Men or women less than 80 years of age * Performance status 0 or 1 * Life expectancy \>12 weeks * Adequate organ-function * Written informed consent Key Exclusion Criteria: * Prior chemotherapy for adenocarcinoma of the esophagus or stomach if the chemotherapy-free interval is less than 6 months * Progression on first-line chemotherapy for unresectable or metastatic adenocarcinoma of the esophagus or stomach * Chemotherapy with epirubicin, oxaliplatin, carboplatin, cisplatin or docetaxel less than 6 months before study entry * Prior cumulative dose of \>300 mg/m2 of epirubicin * Grade ≥ 2 side-effects from previous chemotherapy